Navigation Links
Xytis Names Gordon H. Busenbark as Chief Financial Officer
Date:10/19/2007

IRVINE, Calif., Oct. 19 /PRNewswire/ -- Xytis Inc., a privately held biotechnology company focused on developing novel therapeutics to treat central nervous system (CNS) diseases, today announced that Gordon H. Busenbark has joined the company as Chief Financial Officer. Mr. Busenbark has more than 25 years of experience in the pharmaceutical, biotechnology and medical devices industries. During a 23 year career at Baxter Healthcare, Mr. Busenbark held a number of senior-level financial, operational and general management positions in both the U.S. and Europe. This included roles as Chief Financial Officer of Immuno AG when the company was acquired by Baxter, and President of Baxter's global Plasma Therapeutics business. Mr. Busenbark's most recent role was as Chief Financial Officer at Encysive Pharmaceuticals, where his accomplishments included raising more than $100 million in debt and equity financing.

"We are very pleased to have Gordon join Xytis," said Vincent F. Simmon, CEO and President. "He brings great financial and operational experience, both from a large pharmaceutical company perspective as well as from that of a smaller biotechnology company. Gordon joins us at an exciting time for Xytis. Our Phase 2 clinical trial in Traumatic Brain Injury (TBI) is approximately half way enrolled. Also, there is considerable partnering interest in two of our pre-clinical programs; positive allosteric modulators of GABA-A receptor and of alpha-7 nicotinic acetylcholine receptors. His experience and assistance in financing and marshalling these programs forward will be greatly welcomed."

Mr. Busenbark has both a B.S. in Accounting and an MBA from the University of Utah.

About Xytis

Xytis Inc. is a privately held discovery and development biopharmaceutical company, headquartered in Irvine, California, and having a clinical development group in Nyon, Switzerland, focused on innovative CNS drug candidates. The Company's investors include At
'/>"/>

SOURCE Xytis Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... LEESBURG, Va. , Jan. 14, 2014 Animal Emergency Critical ... in Leesburg, Virginia is the first in ... hyperbaric oxygen chamber. Dr. Susan M. Barnes ... years. Dr. Barnes and husband, Dr. Cole Taylor , are ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
(Date:1/14/2014)... January 14, 2014 Equashield ( ... hazardous drugs, today announced that it has achieved ... year.   Equashield,s closed systems reduce ... nurses and other medical professionals who prepare and ...
Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
... THOUSAND OAKS, Calif., March 4, 2011 Amgen (Nasdaq: ... the acquisition of BioVex Group, Inc., a privately held ... in Abingdon, UK. The acquisition includes OncoVEX(GM-CSF), a novel ... may represent a new approach to treating melanoma and ...
... Nephros, Inc. (OTC Bulletin Board: NEPH ... products for therapeutic applications, infection control, and water purification, ... private placement that together will result in gross proceeds ... is pleased to have successfully completed its shareholders rights ...
Cached Medicine Technology:Amgen Completes Acquisition of BioVex 2Amgen Completes Acquisition of BioVex 3Amgen Completes Acquisition of BioVex 4Nephros Announces $3.2 Million Financing Through Completion of Rights Offering and Private Placement Transactions 2Nephros Announces $3.2 Million Financing Through Completion of Rights Offering and Private Placement Transactions 3Nephros Announces $3.2 Million Financing Through Completion of Rights Offering and Private Placement Transactions 4
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... 17, 2014U.S. military personnel who served in Iraq ... traumatic brain injury (TBI) were compared to military ... medical reasons. Differences in measures of overall disability, ... after injury are reported in an article in ... from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2
... at the Swedish medical university Karolinska Institutet have discovered ... inflammatory substances in their brains. Their findings offer hope ... affect the immune system. The causes of ... of effective treatments. One theory is that infections caught ...
... stimulates collagen production in fibroblasts and hepatic stellate ... the development of liver fibrosis. Hepatoprotective effects of ... induced liver fibrosis were reported in many studies. ... dimethylnitrosamine (DMN)-induced models has not been studied. ...
... or stall carotid artery disease , WEDNESDAY, Nov. 18 ... no additional benefit to seniors with coronary artery disease ... say. , The 18-month study of 145 Baltimore-area men ... in arterial wall thickness reductions between those who took ...
... quickly is critical, experts say , WEDNESDAY, Nov. 18 ... and communities in new guidelines for treatment of coronary ... should have an organized system of emergency care for ... they get to hospitals and strategies for getting ...
... , ... of the StreetSmarts® sales knowledge sharing platform and ELA’s sales expertise offers a winning ... ... Inc., developer of the on-demand sales effectiveness , knowledge and collaboration ...
... , LONDON, Nov. 18 XL Insurance, the global insurance ... today announced the strengthening of its equine capabilities with the ... Underwriting Limited ("Unicorn"), a subsidiary of THB Group plc. ... who has over 20 years of underwriting experience in the ...
Cached Medicine News:Health News:Immune system activated in schizophrenia 2Health News:Niacin Adds No Benefit for Statin Patients: Study 2Health News:New Heart Attack Treatment Guidelines Stress Coordination 2Health News:New Heart Attack Treatment Guidelines Stress Coordination 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 4Health News:XL Insurance Strengthens Equine Underwriting Team 2
A convenient, rotating standholds up to seven Gilson pipettes (any model) with exceptional stability. Protects your precious pipettes from possible damage or contamination....
Inquire...
... solution for scheduling, performing and documenting ... pipettes and liquid handling devices. Collects ... Supports all gravimetric calibration protocols ... NCCLS and GLP requirements Includes ...
... V-shaped bottom allows easy withdrawal of solution ... bag ,• Corner pouring lips facilitate ... designed for 4, 8, and 12 channel ... withdrawal of practically all of the solution. ...
Medicine Products: